SINGAPORE (Reuters) - Grab, the biggest rival to ride-sharing service Uber Technologies Inc [UBER.UL] in Southeast Asia, has raised $750 million in a funding round, turning up the heat on the U.S. firm now seeking to expand in the region after exiting China.

SHANGHAI (Reuters) - China's nuclear developers must seek the consent of local stakeholders before going ahead with new projects, according to draft rules published by the country's cabinet on Monday.

FRANKFURT (Reuters) - Twilio Inc. isn't a name many consumers will recognize, even though it has recently led a modest revival in the U.S. market for technology initial public offerings by nearly quadrupling in value since its stock market debut in June.

KHARTOUM (Reuters) - Egypt, Sudan and Ethiopia commissioned studies into the environmental and economic impact of a $4 billion dam on the Nile that Addis Ababa aims to make the centerpiece of its bid to become Africa's biggest power exporter.

MUMBAI (Thomson Reuters Foundation) - Two people were killed and about 20 injured in the eastern Indian state of Assam, when protesters clashed with police over evictions of encroachers around a wildlife park.

LONDON (Reuters) - GlaxoSmithKline said on Tuesday it had chosen its head of consumer healthcare, Emma Walmsley, as its new chief executive, after several months reviewing internal and external candidates.

SEOUL (Reuters) - North Korean leader Kim Jong Un supervised a ground test of a new rocket engine to launch satellites, the North's state media reported on Tuesday, the latest in a rapid succession of missile-related tests this year by the isolated state.

BEIJING (Reuters) - China's central bank may provide low-cost loans to banks to help them finance environmental projects, the official Securities Times reported on Tuesday, quoting the central bank's chief economist.

FRANKFURT (Reuters) - German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.